Fig. 2

Proliferation and migration of human BM-MSCs (hBM-MSCs) treated or pre-treated with IGF-1, IL-4, IL-6, or SDF-1. a The experimental design. b The number of hBM-MSCs non-treated (NT) or treated with either IGF-1, IL-4, IL-6, or SDF-1 and cultured in the proliferating medium (PM) for 7 days (n = 3). c The number of hBM-MSCs non-treated (NT) or treated with either IGF-1, IL-4, IL-6, or SDF-1 and cultured in the differentiating medium (DM) for 7 days (n = 3). d The number of hBM-MSCs pre-treated with either IGF-1, IL-4, IL-6, or SDF-1 for 3 days and cultured in the proliferating medium (PM), analyzed after 1, 3, and 7 days (n = 3). e The migration of hBM-MSCs non-treated (NT) and treated either with IGF-1, IL-4, IL-6, or SDF-1 cultured in the proliferating medium (PM) and analyzed after 6 h and 12 h (n = 3). *p < 0.05, **p < 0.01, ***p < 0.005